Pituitary / ADH Agents

Verified · Oct 2026

Prototype: desmopressin

Pituitary / ADH Agents are a class of medications used for central diabetes insipidus.

Medical view → mechanisms, drug comparisons and Step 1 pharmacology

Desmopressin and vasopressin — turning the kidney’s water tap back on, and why too much water becomes the emergency.

How it works in the body

The system involved, what goes wrong, and how the drug and body interact.

01 ADH — the body’s water-conservation hormone

The posterior pituitary releases antidiuretic hormone (ADH, vasopressin) when the body needs to hold on to water. ADH travels to the kidney and stimulates V2 receptors on the collecting duct, which insert aquaporin water channels into the tubule wall. Water is then pulled back into the blood, producing concentrated urine and defending the body’s fluid volume and sodium concentration.

When ADH is missing — central diabetes insipidus (DI) — the kidney cannot reabsorb water, so the patient makes huge volumes of dilute urine and is perpetually thirsty (polyuria and polydipsia). The fix is to replace the hormone with desmopressin (DDAVP), a synthetic ADH analog that switches the water-conservation system back on.

Loading diagram…

ADH/desmopressin → V2 receptor → aquaporins inserted → water reabsorbed → concentrated urine, conserved water.

02 Desmopressin’s second job — stopping bleeding

Desmopressin has a valuable second action unrelated to urine: it triggers the release of von Willebrand factor and factor VIII from the lining of blood vessels. That temporarily boosts clotting, so desmopressin is also used to treat bleeding in mild-to-moderate type 1 von Willebrand disease, mild hemophilia A, and uremic (kidney-failure) platelet dysfunction. It is V2-selective, meaning it delivers the water-conserving effect with little of vasopressin’s blood-pressure (V1) effect — making it the gentler, more targeted drug.

Its uses therefore split into two families: antidiuretic (central DI, bedwetting/primary nocturnal enuresis) and hemostatic (bleeding disorders). The antidiuretic water-holding power is also the source of its one big danger, whatever the indication.

03 The overshoot — water intoxication and hyponatremia

Because desmopressin makes the kidney retain water, a patient who keeps drinking normally can accumulate too much water — diluting the blood’s sodium into hyponatremia. This "water intoxication" is the defining hazard of the class: falling sodium causes headache, nausea, confusion, and, if severe, cerebral edema and seizures. The elderly, young children, and patients on NSAIDs (among other interacting drugs) are at greater risk.

The safety strategy follows directly: restrict fluid intake to thirst, monitor serum sodium and daily weights, and teach patients to report headache or confusion. By contrast, the natural hormone vasopressin — which also strongly activates V1 receptors (vasoconstriction) — is used as a vasopressor in septic/vasodilatory shock and to control variceal GI bleeding; there the risk shifts to tissue ischemia from intense vasoconstriction.

Loading diagram…

Desmopressin holds water; unrestricted drinking → dilutional hyponatremia → cerebral edema/seizures. Restrict fluids, watch sodium.

Drug names

Generic Brand

desmopressin DDAVP, Stimate

vasopressin Vasostrict

* DDAVP, Stimate (desmopressin): Drugs@FDA lists the Stimate brand as discontinued, although Ferring still has a current Stimate label (2026).

Indications

Central (ADH-deficient) diabetes insipidus — desmopressin
Primary nocturnal enuresis — desmopressin tablets (the nasal spray is not indicated for enuresis)
Bleeding in mild-to-moderate type 1 von Willebrand disease and hemophilia A when factor VIII levels are above 5%, and uremic platelet dysfunction — desmopressin (not severe type 1 disease, and not type 2B, where it may cause thrombocytopenia and possibly thrombosis)
Vasodilatory (e.g., septic) shock that stays hypotensive despite fluids and catecholamines — vasopressin (V1 vasopressor); also used off-label for variceal bleeding

Mechanism of action

Desmopressin is a synthetic, V2-selective vasopressin analog: it activates renal collecting-duct V2 receptors to insert aquaporin-2 channels, increasing water reabsorption (antidiuresis), and stimulates endothelial release of von Willebrand factor and factor VIII (hemostasis). Native vasopressin also activates V1 receptors on vascular smooth muscle, causing vasoconstriction and raising blood pressure.

In plain terms

Desmopressin tells the kidney to keep water (and helps blood clot); vasopressin does that plus squeezes blood vessels to raise pressure.

Therapeutic effects — what you'll see working

Success is controlled urine output and normal serum sodium (DI), a dry night (enuresis), or stopped bleeding — achieved without tipping the patient into water overload.

Reduced urine output (antidiuresis) Improved hemostasis Raised blood pressure (vasopressin)

Reduced urine output (antidiuresis): Restored water reabsorption concentrates the urine and relieves the polyuria/polydipsia of central DI.
Improved hemostasis: Released von Willebrand factor and factor VIII temporarily correct bleeding in mild-to-moderate type 1 vWD, mild hemophilia A, and uremia.
Raised blood pressure (vasopressin): V1-mediated vasoconstriction supports perfusion in vasodilatory/septic shock as an adjunct vasopressor.

Adverse effects

For desmopressin the central safety concern is too much water; for vasopressin it is too much vasoconstriction.

Serious — hyponatremia / water intoxication (desmopressin) Report immediately

Water retention with continued drinking → dilutional hyponatremia → headache, confusion, cerebral edema, seizures. Greater risk in the elderly, young children, and with other drugs that can lower sodium — tricyclic antidepressants, SSRIs, chlorpromazine, opioid analgesics, NSAIDs, lamotrigine, carbamazepine (the injection label adds thiazide diuretics, chlorpropamide and other sulfonylureas, and oxybutynin) — which call for more frequent sodium checks.

Prevent it: restrict fluids, monitor serum sodium and daily weight. Treat it by interrupting or stopping desmopressin and restricting fluids, with hypertonic saline for severe symptoms such as seizures — do not simply flood with water.

Serious — vasoconstriction/ischemia (vasopressin)

Intense V1 vasoconstriction can cause hypertension, and cardiac, mesenteric, or digital ischemia.

Given in critical care with hemodynamic monitoring; watch for chest pain, abdominal pain, and cool/mottled extremities.

Common

Headache, nausea, flushing, abdominal cramps; nasal irritation/congestion with the intranasal spray.

Usually mild and dose-related. A new or worsening headache warrants a sodium check, since it can be the first sign of hyponatremia.

■ Boxed warning — hyponatremia (desmopressin injection) Report immediately

DDAVP Injection — hyponatremia, which can be severe and life-threatening.

DDAVP Injection carries a boxed warning: desmopressin can cause hyponatremia, and severe hyponatremia can lead to seizures, coma, respiratory arrest, or death. It is contraindicated in patients at increased risk — excessive fluid intake, illnesses that cause fluid or electrolyte imbalance, and use of loop diuretics or systemic or inhaled glucocorticoids. Confirm a normal serum sodium before starting or resuming, check it within 7 days and about 1 month after starting and periodically after that (more often at 65 or older and in others at increased risk of hyponatremia), and interrupt or stop the drug if hyponatremia occurs.

Contraindications

Most contraindications are the states where extra water retention (or, for vasopressin, vasoconstriction) is dangerous; type 2B von Willebrand disease is the exception, where desmopressin can cause platelet aggregation, thrombocytopenia, and possibly thrombosis.

Hyponatremia or a history of it (all desmopressin labels); known or suspected SIADH (injection and Stimate labels)

Adding water retention to an already low or over-diluted sodium risks severe, symptomatic hyponatremia.

Moderate-to-severe renal impairment (creatinine clearance < 50 mL/min) — desmopressin

Impaired free-water excretion greatly increases the risk of water intoxication.

Desmopressin injection — heart failure, uncontrolled hypertension, polydipsia, illnesses that can cause fluid or electrolyte imbalance (e.g., gastroenteritis, salt-wasting nephropathy, systemic infection), or use of loop diuretics or systemic/inhaled glucocorticoids

Labeled contraindications for DDAVP Injection: fluid retention can worsen heart failure and hypertension, and polydipsia or these drugs raise the risk of severe hyponatremia.

Other desmopressin forms — conditions with fluid overload (e.g., heart failure) or polydipsia use caution

These patients cannot handle the added water load and are prone to dilutional hyponatremia — use with caution and close sodium monitoring.

Desmopressin in very young children (especially under 2 years) use caution

Their water and fluid intake is hard to restrict, so StatPearls advises avoiding desmopressin in younger patients, especially under age 2; the Stimate label says not to use it in infants younger than 11 months for hemophilia A or von Willebrand disease.

Vasopressin — heart disease or peripheral vascular disease (patients vulnerable to ischemia or with poor cardiac function) use caution

V1 vasoconstriction can cause myocardial, mesenteric, or limb ischemia and can lower cardiac index.

Desmopressin (Stimate) — type 2B von Willebrand disease

A labeled contraindication: in type 2B disease desmopressin can cause platelet aggregation, thrombocytopenia, and possibly thrombosis.

When to hold

Assess before giving — these findings mean hold the dose and act.

Signs of water intoxication — headache, confusion, or unrestricted drinking

Water intoxication / hyponatremia is a major risk — restrict fluid intake, monitor serum sodium and daily weight, and report headache, confusion, or seizures.

Labs & levels

Test Therapeutic / normal Toxic / critical

Serum sodium Confirm a normal sodium before starting or resuming desmopressin; recheck within 7 days and about 1 month after starting, then periodically (more often at 65 or older or with other hyponatremia risks — DDAVP Injection boxed warning); daily weights during therapy Normal range 135–145 mEq/L Dilutional hyponatremia — headache, confusion, cerebral edema, seizures

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Fluid & sodium safety

Monitor serum sodium, daily weight, and intake/output; assess for headache, confusion, or seizures (water intoxication).

Why: Desmopressin’s water retention can dilute sodium dangerously; weight gain and neuro changes are early clues.

Teach patients (and enuresis families) to limit fluids — especially in the evening for bedwetting — and to report headache, nausea, or confusion.

Why: Restricting free water is a labeled step to prevent hyponatremia.

Administration

Give vasopressin in a monitored setting and watch for ischemia/hypertension; titrate as ordered.

Why: Its potent V1 vasoconstriction can compromise cardiac, mesenteric, and peripheral perfusion.

After vasopressin is stopped, monitor urine output, fluid status, and serum electrolytes.

Why: Reversible diabetes insipidus — large volumes of dilute urine with rising sodium — can follow discontinuation; some patients need vasopressin restarted or desmopressin.

For intranasal desmopressin, teach correct technique and assess for nasal irritation; verify the specific product/route (nasal, oral, SC/IV differ in potency).

Why: Routes are not interchangeable milligram-for-milligram; dosing errors risk under- or over-treatment.

Common questions

What are Pituitary / ADH Agents used for?

Pituitary / ADH Agents are used for central diabetes insipidus; primary nocturnal enuresis; bleeding in mild-to-moderate type 1 von Willebrand disease and hemophilia A when factor VIII levels are above 5%, and uremic platelet dysfunction; and vasodilatory shock that stays hypotensive despite fluids and catecholamines.

How do Pituitary / ADH Agents work?

Desmopressin tells the kidney to keep water (and helps blood clot); vasopressin does that plus squeezes blood vessels to raise pressure.

What are the serious side effects of Pituitary / ADH Agents?

Watch for (with desmopressin) water retention with continued drinking → dilutional hyponatremia → headache, confusion, cerebral edema, seizures. Greater risk in the elderly, young children, and with other drugs that can lower sodium — tricyclic antidepressants, SSRIs, chlorpromazine, opioid analgesics, NSAIDs, lamotrigine, carbamazepine (the injection label adds thiazide diuretics, chlorpropamide and other sulfonylureas, and oxybutynin) — which call for more frequent sodium checks; (with vasopressin) intense V1 vasoconstriction can cause hypertension, and cardiac, mesenteric, or digital ischemia; DDAVP Injection — hyponatremia, which can be severe and life-threatening.

When should a nurse hold Pituitary / ADH Agents, and what safety checks apply?

Signs of water intoxication — headache, confusion, or unrestricted drinking: water intoxication / hyponatremia is a major risk — restrict fluid intake, monitor serum sodium and daily weight, and report headache, confusion, or seizures.

What labs should be monitored with Pituitary / ADH Agents?

Monitor serum sodium.

Conditions treated

Hemophilia & von Willebrand Disease

Patho · Hematologic

Desmopressin (DDAVP) — scoped use. In mild hemophilia A "desmopressin (DDAVP) can be used as a first-line therapy for minor to moderate bleeding"; in VWD it treats "milder forms of VWD (mainly type 1)." It releases stored factor VIII and VWF. Not for hemophilia B; "Type 3 von Willebrand disease does not respond"; StatPearls trials it in "type 1, some type 2 (except type 2B)." A trial is needed first. Watch sodium: "Hyponatremia is the major adverse effect; therefore, fluid restriction is required." "tachyphylaxis typically occurs after 3 to 4 doses"; "DDAVP is contraindicated in children younger than 3 due to seizure risk"; it carries a thrombosis risk.

SIADH & Diabetes Insipidus

Patho · Endocrine

This class covers both ends of the axis. Desmopressin (DDAVP) is first-line for central DI (AVP-D) and useless in nephrogenic DI (AVP-R) — which is exactly why the desmopressin challenge is also the diagnostic test. It can be given orally, intranasally, subcutaneously or intravenously, and the prescribing principle is minimalist: "the minimum dose should be administered to control polyuria adequately," because the drug’s therapeutic effect is water retention and its dose-limiting toxicity is hyponatremia. It is considered safe in pregnancy. The specific nursing rule — check urine specific gravity and osmolality before giving a post-operative dose — exists because a patient entering the antidiuretic phase after pituitary surgery does not need more antidiuresis. Going the other way, vaptans (V2-receptor antagonists — conivaptan IV, tolvaptan oral) are the mirror-image drug used in SIADH, blocking AVP at the collecting duct to increase water excretion toward a goal sodium above 130 mEq/L; they demand intensive inpatient monitoring in severe hyponatremia, and tolvaptan has caused overcorrection at doses of 3.75 mg and above. And in a neat symmetry, desmopressin is also the rescue agent when a sodium correction has run too fast.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Always verify against current prescribing information and your institution's protocols before administering. Not medical advice.